Everything below concerns nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
There are various reasons for replacing lost bone tissue and encouraging natural bone growth, and each technique tackles jawbone defects differently. Reasons that bone grafting might be needed include sinus augmentation, socket preservation, ridge augmentation, or regeneration. There is currently some evidence supporting the use of autologous platelet concentrates (cell fragments containing growth factors to promote tissue regeneration) when bone grafting is used to treat gum disease.
Lucy Letby (born 4 January 1990) is a British former NHS neonatal nurse convicted of murdering seven babies and attempting to murder seven others at the Countess of Chester Hospital in Chester between June 2015 and June 2016. She was investigated after an unusual cluster of deaths in the hospital's neonatal unit. Charged in November 2020 with seven counts of murder and fifteen counts of attempted murder relating to seventeen babies, Letby was prosecuted on the basis of her presence at many of the incidents, two abnormal blood test results and skin discolouration interpreted as signs of insulin poisoning and air embolism, inconsistencies in medical records, her removal of nursing handover sheets from the hospital, and handwritten notes interpreted by the prosecution as a confession. In August 2023, she was found guilty on seven counts each of murder and attempted murder, and acquitted on two counts of attempted murder. The jury was unable to reach verdicts on six further counts. She received fourteen whole life orders, meaning life imprisonment without the possibility of parole. One of the unresolved attempted murder charges was retried in July 2024, resulting in a fifteenth whole life order. The senior management of the Countess of Chester Hospital was criticised for failing to act on clinicians' concerns, prompting the British government to commission an independent inquiry. Cheshire Police examined extra cases, resulting in three arrests related to corporate manslaughter. Two applications for permission to appeal have been refused by the Court of Appeal.
=== Japan === Manfred Kiese at the Pharmacological Institute in Berlin published a survey of literature on antibiotics in the 7 August 1943 issue of Klinische Wochenschrift that included the Oxford team's publications. A copy was acquired by the Japanese embassy in Berlin and taken to Japan on the Japanese submarine I-8, which docked at Kure, Hiroshima, on 21 December 1943. The article was translated into Japanese, and production of penicillin was underway by 1 February 1944. By mid-May, a research team under Hamao Umezawa had tested 750 different strains of mould and found that 75 exhibited antibiotic activity. Experiments were conducted on mice to determine efficacy and toxicity. The Morinaga Milk company had a small penicillin production plant in operation in Mishima, Shizuoka, by the end of the year, and the Banyu Pharmaceutical Company opened a small plant in Okazaki, Aichi, in January 1945. The penicillin was called "Hekiso" after its blue colour. By 1948 Japan had become the third country, after the US and UK, to become self-sufficient in penicillin, and exports to China and Korea began the following year.
Sources: en.wikipedia.org
hard acid A Lewis acid with an electron-accepting centre that is only weakly polarizable. Hard acid species also tend to have high charge states and relatively small atomic nuclei, in contrast to soft acids.
=== Melamine production and use in China === Melamine is commonly produced from urea, mainly by either catalyzed gas-phase production or high pressure liquid-phase production, and is soluble in water. Melamine is used combined with formaldehyde to produce melamine resin, a very durable thermosetting plastic, and melamine foam, a polymeric cleaning product. The end products include counter-tops, fabrics, glues and flame retardants. Occasionally, melamine-formaldehyde resin is added to gluten for non-food purposes, such as adhesives or fabric printing. Melamine is also a byproduct of several pesticides, including cyromazine. The Food Safety and Inspection Service (FSIS) of the United States Department of Agriculture (USDA) provides a test method for analyzing cyromazine and melamine in animal tissues in its Chemistry Laboratory Guidebook which "contains test methods used by FSIS Laboratories to support the Agency's inspection program, ensuring that meat, poultry, and egg products are safe, wholesome and accurately labeled." In 1999, in a proposed rule published in the Federal Register regarding cyromazine residue, the United States Environmental Protection Agency (EPA) proposed "remov[ing] melamine, a metabolite of cyromazine from the tolerance expression since it is no longer considered a residue of concern." Melamine production in China has also been reported as using coal as raw material.
== Sources == "Leslie Stephen Ettre," Obituary, Hartford Courant, June 4, 2010. C. W. Gerhke, Chromatography: A Century of Discovery 1900–2000 : The Bridge to the Sciences/Technology Journal of Chromatography Library Vol. 64 (Elsevier, 2001), pp. 178 – 179. "Happy Birthday Professor Leslie S. Ettre," Chromatographia, (2007) 66 (5–6), 301.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.